Factors affecting Naseptin treatment success - A prospective cohort study.

Autor: Garry S; Department of Otolaryngology, Children's Health Ireland at Temple Street, Dublin 1, Ireland; Department of Surgery, Royal College of Surgeons, Dublin 2, Ireland. Electronic address: stephengarry@rcsi.com., Wauchope J; Department of Otolaryngology, Children's Health Ireland at Temple Street, Dublin 1, Ireland; Department of Surgery, Royal College of Surgeons, Dublin 2, Ireland., Hintze JM; Department of Surgery, Royal College of Surgeons, Dublin 2, Ireland., Ryan EJ; Department of Surgery, Royal College of Surgeons, Dublin 2, Ireland., O'Cathain E; Department of Otolaryngology, Children's Health Ireland at Temple Street, Dublin 1, Ireland; Department of Surgery, Royal College of Surgeons, Dublin 2, Ireland., Heffernan CB; Department of Otolaryngology, Children's Health Ireland at Temple Street, Dublin 1, Ireland; Department of Surgery, Royal College of Surgeons, Dublin 2, Ireland.
Jazyk: angličtina
Zdroj: International journal of pediatric otorhinolaryngology [Int J Pediatr Otorhinolaryngol] 2023 Aug; Vol. 171, pp. 111620. Date of Electronic Publication: 2023 Jun 17.
DOI: 10.1016/j.ijporl.2023.111620
Abstrakt: Objective: To assess patient factors to predict treatment success of Naseptin for recurrent paediatric epistaxis.
Methods: This prospective cohort study of paediatric patients referred to a tertiary paediatric otolaryngology clinic with recurrent epistaxis treated with Naseptin cream and education. Patients with red flag symptoms and bleeding diathesis were omitted, along with patients with concurrent otolaryngology complaints. Statistical analysis included logistic regression analysis to assess for predictive factors contributing to treatment success.
Results: 125 of 210 patients on the waiting list met the inclusion criteria and were given a complete trial of Naseptin. 80.8% (n = 101) of patients found that the frequency and severity of epistaxis had reduced, with the remaining 19.2% (n = 24) reporting that the episodes of epistaxis remained the same and required further management (i.e., silver nitrate cautery). Five patients (4%) reported minor side effects (skin irritation etc.) with no significant adverse events reported.
Conclusion: We found that Naseptin is a safe, well-tolerated treatment that should be trialled in most cases of recurrent paediatric epistaxis. Most children will benefit from it with complete epistaxis cessation or at least reduced frequency and severity.
Competing Interests: Declaration of competing interest The authors declare no conflicts of interest.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: